| 6.77 -0.874 (-11.44%) | 08-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.68 |
1-year : | 9.57 |
| Resists | First : | 7.43 |
Second : | 8.19 |
| Pivot price | 7.09  |
|||
| Supports | First : | 6.19 |
Second : | 5.15 |
| MAs | MA(5) : | 7.43 |
MA(20) : | 6.99 |
| MA(100) : | 6.86 |
MA(250) : | 7.35 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 51.4 |
D(3) : | 61.8 |
| RSI | RSI(14): 44.2 |
|||
| 52-week | High : | 8.92 | Low : | 5.98 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CUVL ] has closed above bottom band by 29.7%. Bollinger Bands are 90.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.97 - 8.01 | 8.01 - 8.06 |
| Low: | 6.67 - 6.71 | 6.71 - 6.75 |
| Close: | 6.71 - 6.78 | 6.78 - 6.84 |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Thu, 27 Aug 2026
Clinuvel Pharmaceuticals (CUVL) shares annual report and ASX materials - Stock Titan
Thu, 27 Aug 2026
A decade of profitability provides foundation for CLINUVEL’s U.S. expansion - markets.businessinsider.com
Mon, 24 Aug 2026
CUVL PE Ratio & Valuation, Is CUVL Overvalued - Intellectia AI
Thu, 20 Aug 2026
Clinuvel (Nasdaq: CUVL) sets date for 2026 annual results - Stock Titan
Wed, 12 Aug 2026
Clinuvel (CUVL) refines VLRX-L injectable peptide candidate after positive data - Stock Titan
Thu, 23 Jul 2026
CLINUVEL implements strategic reorganisation to refocus on U.S. markets - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 50 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.53 |
| Profit Margin | 33.7 % |
| Operating Margin | 36.5 % |
| Return on Assets (ttm) | 10.6 % |
| Return on Equity (ttm) | 13.9 % |
| Qtrly Rev. Growth | 3.5 % |
| Gross Profit (p.s.) | 1.71 |
| Sales Per Share | 1.9 |
| EBITDA (p.s.) | 0.86 |
| Qtrly Earnings Growth | -26.3 % |
| Operating Cash Flow | 40 (M) |
| Levered Free Cash Flow | 32 (M) |
| PE Ratio | 14.71 |
| PEG Ratio | 0 |
| Price to Book value | 1.91 |
| Price to Sales | 3.54 |
| Price to Cash Flow | 8.43 |
| Dividend | 0.02 |
| Forward Dividend | 0 |
| Dividend Yield | 0.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|